CRISPR Guide RNA Design for Allele-Specific RPS19 Editing

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current methods are inadequate for effectively targeting and correcting dominant disease-associated mutations in genes, such as those causing Diamond Blackfan anemia, particularly in the RPS19 gene, which affects ribosomal function and leads to bone marrow issues and anemia.

Innovation Solution

The use of RNA-guided DNA nucleases, specifically CRISPR technology, to differentiate between mutant and wild-type alleles by designing guide RNAs that target specific nucleotide differences, allowing for allele-specific editing and correction through homology-directed repair, thereby restoring functional protein expression.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Manufacturing precision

If CRISPR technology is used to target mutant alleles, then gene editing precision is improved, but difficulty of detecting and measuring increases

Engineering Contradiction:
Improvegene editing precisionVSAvoidallele differentiation difficulty
Core Design Contradiction:
Manufacturing precisionVSDifficulty of detecting and measuring

Solution Approach 1:

The guide RNA is designed to recognize specific local sequence differences (SNPs or mutations) at the target allele location, enabling precise differentiation between mutant and wild-type alleles through localized sequence matching rather than requiring comprehensive genomic analysis

Inventive Principle:
Principle #3Local quality

Solution Approach 2:

A detectable marker system is introduced as an intermediary to signal successful allele targeting and editing events, converting the invisible molecular changes into detectable signals that facilitate measurement and verification of gene editing outcomes

Inventive Principle:
Principle #24Intermediary (Mediator)

2Reliability

If allele-specific guide RNA is designed to target mutant alleles, then gene editing specificity is improved, but device complexity increases

Engineering Contradiction:
Improveallele editing specificityVSAvoidguide RNA design complexity
Core Design Contradiction:
ReliabilityVSDevice complexity

Solution Approach 1:

The guide RNA molecule is segmented into distinct functional domains: a target-binding region that recognizes specific mutant allele sequences and a spacer region that positions the nuclease for cleavage, allowing systematic design of allele-specific guides through modular sequence selection

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

Specific parameters of the guide RNA are adjusted to optimize allele specificity, including modifying the length of the target-binding region (17-25 nucleotides), adjusting GC content (40-60%), and selecting specific nucleotide compositions to enhance discrimination between mutant and wild-type alleles

Inventive Principle:
Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach enables precise correction of mutant alleles, potentially alleviating the symptoms of Diamond Blackfan anemia by enhancing ribosomal function and improving blood cell production.

Implementation Method 1

a complex of the CRISPR nuclease and the first RNA molecule affects a double strand break in a non-coding region of the RPS19 gene at a location that is 250 or fewer nucleotides from the first or the last nucleotide of a coding region

Methodology Applied
Scientific EffectCRISPR nuclease activity: Enzyme

Data Source

PatentUS20220098621A1Crispr compositions and methods for promoting gene editing of ribosomal protein s19 (RPS19) gene
Publication Date: 2022.03.31 EMENDOBIO INC
  • US20220098621A1 patent drawing
  • US20220098621A1 patent drawing
  • US20220098621A1 patent drawing

AI summary

RNA molecules comprising a guide sequence portion having 17-25 contiguous nucleotides containing nucleotides in the sequence set forth in any one of SEQ ID NOs 1-20465 and compositions, methods, and uses thereof.